Sign In
18 Aug 2010 14:16
This is a correction of the announcement 2276R from 7.00 on 18.08.2010. Reason for the correction: the number of shares acquired for each director was incorrect. The corrected version is set out below.
18 August 2010
Cyprotex PLC ("Cyprotex" or the "Company")
Director dealings
Macclesfield, UK - Cyprotex PLC (LSE: CRX), a Contract Research Organisation (CRO) specialising in the preclinical ADME assessment of drug candidates, was informed on 17 August 2010 that certain directors acquired ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") on 17 August 2010. Details of the dealings are set out below:
|
Name |
Title |
Price |
Shares acquired |
Total interest following dealing |
% of total issued share capital |
|
Steve Harris |
Chairman |
3.50 |
707,142 |
1,507,142 |
0.67 |
|
Anthony Baxter |
Chief Executive Officer |
3.50 |
226,285 |
1,067,685 |
0.48 |
|
John Dootson |
Chief Financial Officer |
3.50 |
589,285 |
589,285 |
0.26 |
|
Katya Tsaioun |
Chief Scientific Officer |
3.50 |
1,767,857 |
24,133,006 |
10.79 |
|
Douglas Bates |
Chief Marketing Officer |
3.50 |
5,303,571 |
27,668,719 |
12.37 |
For further information please contact:
|
Cyprotex PLC |
Tel: +44 1625 505 100 |
|
Dr. Anthony Baxter, Chief Executive Officer |
|
|
a.baxter@cyprotex.com |
|
|
www.cyprotex.com |
|
|
|
|
|
Singer Capital Markets Ltd |
Tel: +44 203 205 7500 |
|
Shaun Dobson |
|
|
Claes Spång |
|
|
|
|
|
Financial Dynamics |
Tel: +44 207 831 3113 |
|
Ben Brewerton |
|
|
Ben Atwell |
|
|
Mo Noonan |
|
|
|
|
Follow the stocks
